findmyKOL
Clinical trialNCT05359653RecruitingPhase 1/PHASE2Interventional

Assessing Changes in Multi-parametric MRI in MS Patients Taking Clemastine Fumarate as a Myelin Repair Therapy

SponsorUniversity of California, San FranciscoEnrollment74Multiple Sclerosis (MS)Multiple Sclerosis BenignMultiple Sclerosis Brain LesionMultiple Sclerosis RelapseMultiple Sclerosis, Chronic ProgressiveMultiple Sclerosis, Primary Progressive+1 more conditions
View the registry record on ClinicalTrials.gov

Summary

The registered summary isn't in our current data snapshot. Read it on the ClinicalTrials.gov record ↗. Why? →

Investigators

The overall officials registered on this study. Names that resolve to a findmyKOL profile link to it; the rest are shown as registered.

A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.

Sites

1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.

United States
  • Sandler Neurosciences Building, Neurological Clinical Research Unit

    San Francisco, California, United States

    Ari J Green, MD
    Recruiting

Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.

Drugs studied

No drug or biological interventions are in our data for this study — it may test a procedure, device or behavioral intervention, or the intervention list isn't in our current snapshot. See the registry record ↗. Why? →

Registration & key dates

Registry attributes as recorded on the ClinicalTrials.gov study record.

Start
1 Aug 2023
Primary completion
1 Jun 2027
Completion
1 Jun 2027
Last update posted
2 Jul 2026
Registered enrollment
74
Registry id
NCT05359653

Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 12 Jul 2026. Registry facts are shown as registered by the study sponsor; findmyKOL does not interpret them.